Your browser doesn't support javascript.
loading
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi, J K; Wirapati, P; Asher, R; Lee, C K; Savas, P; Price, T J; Townsend, A; Hardingham, J; Buchanan, D; Williams, D; Tejpar, S; Mariadason, J M; Tebbutt, N C.
Afiliación
  • Mooi JK; Olivia Newton-John Cancer Research Institute, Heidelberg; Department of Medicine, University of Melbourne, Melbourne, Australia.
  • Wirapati P; Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Asher R; NHMRC Clinical Trials Centre, University of Sydney, Sydney.
  • Lee CK; NHMRC Clinical Trials Centre, University of Sydney, Sydney.
  • Savas P; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne.
  • Price TJ; Medical Oncology, The Queen Elizabeth Hospital, Woodville; School of Medicine, University of Adelaide, Adelaide.
  • Townsend A; Medical Oncology, The Queen Elizabeth Hospital, Woodville; School of Medicine, University of Adelaide, Adelaide.
  • Hardingham J; School of Medicine, University of Adelaide, Adelaide; The Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville.
  • Buchanan D; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Melbourne; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville; Genetic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville.
  • Williams D; Olivia Newton-John Cancer Research Institute, Heidelberg; Department of Pathology, Austin Health, Heidelberg; Department of Pathology, University of Melbourne, Melbourne, Australia.
  • Tejpar S; Oncology, University Hospital Leuven, Leuven, Belgium.
  • Mariadason JM; Olivia Newton-John Cancer Research Institute, Heidelberg; School of Cancer Medicine, La Trobe University, Melbourne.
  • Tebbutt NC; Medical Oncology, Austin Health, Heidelberg, Australia. Electronic address: niall.tebbutt@onjcri.org.au.
Ann Oncol ; 29(11): 2240-2246, 2018 11 01.
Article en En | MEDLINE | ID: mdl-30247524
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Transcriptoma / Bevacizumab Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Transcriptoma / Bevacizumab Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido